logo

For the Inventor, By the Inventor

Scituate, MA, United States of America

Glenn Short

This inventor holds 13 USPTO granted patents and 26 published patent applications. Top assignees: Atai Therapeutics Inc., Empathbio, Inc., Atai Life Sciences Ag. Active years: 2023-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Glenn Short. Retrieved from https://idiyas.com/inventor/glenn-short-4f6icd3b

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 

% Patents Active = 100.0

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 46(Granted Patents)


Company Filing History:

goldMedal7 out of 17 
 
Atai Therapeutics Inc.
 patents
silverMedal3 out of 6 
 
Empathbio, Inc.
 patents
bronzeMedal2 out of 2 
 
Atai Life Sciences Ag
 patents
4. 1 out of 834,513 
Other
 patents

Years Active: 2023-2026

Loading Chart...
13 patents (USPTO):Explore Patents
1. 12606525 - Dimethyltryptamine analogues as nitric oxide delivery drugs (2026-04-21),
2. 12454516 - Nitric oxide releasing prodrugs of MDA and MDMA (2025-10-28),
3. 12351537 - Dimethoxyphenylalkylamine activators of serotonin receptors (2025-07-08),
4. 12344570 - Aminotetraline activators of serotonin receptors (2025-07-01),
5. 12343319 - Compositions and methods for treatment of diseases and disorders (2025-07-01),
6. 12065405 - Prodrugs and conjugates of dimethyltryptamine (2024-08-20),
7. 12012381 - Dimethyltryptamine analogues as nitric oxide delivery drugs (2024-06-18),
8. 11926574 - Dimethoxyphenylalkylamine activators of serotonin receptors (2024-03-12),
9. 11912680 - Nitric oxide releasing prodrugs of MDA and MDMA (2024-02-27),
10. 11845736 - Prodrugs of MDMA, MDA, and derivatives thereof (2023-12-19),
11. 11827580 - Aminotetraline activators of serotonin receptors (2023-11-28),
12. 11643391 - Prodrugs and conjugates of dimethyltryptamine (2023-05-09),
13. 11602521 - N,N-dimethyltryptamine compositions and methods (2023-03-14),

Title: Glenn Short: Innovator in Mental Health Therapeutics

Introduction

Glenn Short is a notable inventor based in Scituate, MA (US), recognized for his contributions to the field of mental health therapeutics. With a total of 12 patents to his name, he has made significant strides in developing innovative pharmaceutical solutions aimed at treating mental health diseases and disorders.

Latest Patents

Among his latest patents are "Nitric oxide releasing prodrugs of MDA and MDMA," which includes compounds of specific formulas designed to enhance therapeutic efficacy. These compounds are intended for use in pharmaceutical compositions that target mental health conditions. Another significant patent is for "Dimethoxyphenylalkylamine activators of serotonin receptors," which also focuses on compounds that can be utilized in treating mental health disorders. Both patents reflect his commitment to advancing mental health treatment options.

Career Highlights

Glenn Short has worked with prominent companies in the pharmaceutical industry, including Atai Therapeutics Inc. and Empathbio, Inc. His work in these organizations has allowed him to collaborate on groundbreaking research and development projects that aim to improve mental health therapies.

Collaborations

Some of his notable coworkers include Robert B Perni and Tanweer A Khan, who have contributed to his innovative projects and research endeavors.

Conclusion

Glenn Short's work exemplifies the intersection of innovation and mental health, showcasing his dedication to improving therapeutic options for individuals facing mental health challenges. His patents and collaborations highlight his significant impact in this vital field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…